secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2021-07-28T23:59:59+00:00
Accession:  0001564590-21-038678
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics enters $125M ATM equity offering; terminates prior $75M facility
--------------------------------------------------------------------------------

- Entered $125M ATM agreement with Stifel, Truist, and H.C. Wainwright for common stock sales at market prices.
- Agents receive 3.0% commission on gross proceeds from sales under the new ATM facility.
- Proceeds to fund continued development of VK2809 and VK0214 programs and general corporate purposes.
- Terminated prior $75M ATM agreement (Aug 2019) with Stifel and Oppenheimer; no shares ever sold under that facility.
- Registration statement for the $125M offering filed but not yet effective; shares may not be sold until effective.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000156459021038678/0001564590-21-038678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000156459021038678/vktx-8k_20210728.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-038678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer